Oscar Health Announces Appointment of Healthcare Veteran Mark Bertolini to CEO; Co-Founder and CEO Mario Schlosser Transitions to President of Technology

Ella Castle

NEW YORK, March 28, 2023–(BUSINESS WIRE)–Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), the first health insurance company built around a full-stack technology platform, today announced the appointment of Mark Bertolini to the role of Chief Executive Officer, effective April 3, 2023. Co-Founder Mario Schlosser, will transition to President of Technology, reporting […]

U.S. News & World Report Announces the 2023 Best Jobs

Ella Castle

Software developer ranks No. 1; health care jobs remain prominent. WASHINGTON, Jan. 10, 2023 /PRNewswire/ — U.S. News & World Report, the global authority in rankings and consumer advice, today announced the 2023 Best Jobs. The rankings offer a look at the best jobs across 17 categories – from sectors […]

Life Time Announces Top Health & Fitness Trends for 2023

Ella Castle

Accredited experts weigh in on mental wellbeing, nutrition, fitness, and more MINNEAPOLIS, Jan. 2, 2023 /PRNewswire/ — Life Time (NYSE: LTH), the nation’s premier healthy lifestyle brand with more than 160 athletic country clubs across North America, is keeping tabs on the emerging trends in all-encompassing wellness as we start 2023. […]

Planet Fitness, Inc. Announces Third Quarter 2020 Results

Ella Castle

HAMPTON, N.H., Nov. 5, 2020 /PRNewswire/ — Today, Planet Fitness, Inc. (NYSE:PLNT) reported financial results for its third quarter ended September 30, 2020. “Today over 95% of our locations are open, with our team members working hard to deliver a safe and healthy in-store environment for our members,” said Chris Rondeau, […]

Ionis announces AstraZeneca’s initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol | News

Ella Castle

CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), an important regulator […]

Subscribe US Now

situs judi bola Daftar sekarang dengan cara klik link login slot via dana 24 jam terpercaya, join sekarang slot gacor online dengan pilihan platform game slot pragmatic play paling favorit tahun 2023.